Goldman Sachs Put 30.03 QIA 20.12.../ DE000GZ6W2V8 /
| 27/06/2024 12:21:33 | Chg.+0.013 | Bid17:55:39 | Ask17:55:39 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.068EUR | +23.64% | 0.069 Bid Size: 10,000 |
0.099 Ask Size: 10,000 |
QIAGEN NV | 30.03 EUR | 20/12/2024 | Put |
GlobeNewswire
13/06
QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput N...
GlobeNewswire
12/06
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to su...
GlobeNewswire
11/06
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious dis...
GlobeNewswire
06/06
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...
GlobeNewswire
05/06
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...
GlobeNewswire
03/06
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...
GlobeNewswire
30/05
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...
GlobeNewswire
30/05
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...
GlobeNewswire
29/05
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...
GlobeNewswire
14/05
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...
GlobeNewswire
13/05
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...
GlobeNewswire
07/05
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
GlobeNewswire
07/05
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
GlobeNewswire
07/05
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
GlobeNewswire
02/05
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...
GlobeNewswire
29/04
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
GlobeNewswire
25/04
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...
GlobeNewswire
24/04
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...
GlobeNewswire
18/04
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...
GlobeNewswire
03/04
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...
